medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Severity of Omicron (B.1.1.529) and Delta (B.1.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study

Dr Catherine Hyams PhD†, Population Health Sciences, University of Bristol, Bristol, UK

Dr Robert Challen MA MBBS†, Engineering Mathematics, University of Bristol, UK

Dr Robin Marlow PhD, Population Health Sciences, University of Bristol, Bristol, UK

Dr Jennifer Nguyen ScD, MPH, Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA

Dr Elizabeth Begier MD, MPH, Global Medical Development Scientific and Clinical Affairs, Pfizer Vaccines, Ireland

Dr Jo Southern PhD, Vaccines Medical Affairs, Pfizer Ltd, Tadworth, UK, KT20 7NS.

Ms Jade King MSc, Vaccine and Testing Team, Clinical Research Facility, UHBW NHS Trust, Bristol, UK

Ms Anna Morley MSc, Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, UK

Ms Jane Kinney BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK

Ms Madeleine Clout BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK

Dr Jennifer Oliver PhD, Bristol Vaccine Centre, Population Health Sciences, University of Bristol, Bristol, UK

Dr Gillian Ellsbury MD, Vaccines Medical Affairs, Pfizer Ltd, Tadworth, UK, KT20 7NS

Prof Nick Maskell MD, Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Dr Luis Jodar PhD Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.

Dr Bradford Gessner PhD, Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.

Dr John McLaughlin PhD, Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA

Dr Leon Danon PhD, Engineering Mathematics, University of Bristol, UK

Professor Adam Finn PhD FRCP, Bristol Vaccine Centre, Cellular and Molecular Medicine and Population Health Sciences, University of Bristol, Bristol, UK (Corresponding Author)

The Avon CAP Research Group

† These authors contributed equally, and should be considered co-first authors

Corresponding Author: Professor Adam Finn, PhD
Bristol Vaccine Centre, University of Bristol
Level 6, UHB Education and Research Centre
Upper Maudlin Street
Bristol BS2 8AE
United Kingdom
+44(0)117 342 0160
adam.finn@bristol.ac.uk

Keywords: COVID-19, SARS-CoV-2, respiratory infection, vaccination

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

ABSTRACT

Limited data exist assessing severity of disease in adults hospitalised with Omicron SARS-CoV-2 variant infections, and to what extent patient-factors, including vaccination and pre-existing disease, affect variant-dependent disease severity. This prospective cohort study of all adults (≥18 years of age) hospitalised at acute care hospitals in Bristol, UK assessed disease severity using 3 different measures: FiO_2 >28%, World Health Organization (WHO) outcome score >5, and hospital length of stay (LOS) >3 days following admission for Omicron or Delta variant infection.

Independent of other variables, including vaccination, Omicron variant infection was associated with a statistically lower severity compared to Delta; risk reductions were 58%, 67%, and 16% for FiO_2, WHO score, and LOS, respectively. Younger age and vaccination with two or three doses were also independently associated with lower COVID-19 severity. Despite lower severity relative to Delta, Omicron infection still resulted in substantial patient and public health burden following admission.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

INTRODUCTION

The emergence of SARS-CoV-2 has resulted in a global pandemic, with multiple variants detected since the wild-type virus emerged. The Delta variant (B.1.617.2) was first detected in India in late March 2021, spread rapidly [1] and resulted in a sharp rise in SARS-CoV-2 cases in the United Kingdom [2]. The Omicron (B.1.1.529) variant, first detected in South Africa in November 2021, rapidly replaced Delta as the main circulating variant globally and resulted in a fourth wave of SARS-CoV-2 infection in the UK. By 26th December 2021, 95% of UK SARS-CoV-2 cases were estimated to be caused by Omicron [3].

SARS-CoV-2 variants may differ in intrinsic capacity to infect and transmit, susceptibility either to vaccine- or infection-derived immunity and clinical phenotype including disease severity. Laboratory data suggest that vaccine-induced neutralizing antibody activity is lower against Delta [4,5] and Omicron variants [6,7] than against previous variants and wild/prototype viral strains. Real world data have subsequently confirmed that vaccine effectiveness is substantially lower against symptomatic disease with Omicron than with Delta and other prior variants [8,9]. However, numbers of hospitalisations as a proportion of cases during the Omicron wave have been considerably lower than previous waves [2,10]. Moreover, observational data suggest that vaccines remain effective against Omicron-related hospitalization in the general population [11,12]. It remains uncertain to what extent the Omicron variant is intrinsically less severe than earlier variants and how much increasing vaccine coverage over time instead explains the observed reduction in severity. Understanding the reasons for differences in clinical disease caused by SARS-CoV-2 variants assists planning and implementation of public health measures.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Several reports [13-16] have compared the risk of hospitalization or severe disease based on SARS-CoV-2 variant and some suggest that Omicron is probably less severe than Delta in both vaccinated and unvaccinated individuals [13-15]. Lower vaccine effectiveness against severe disease due to Omicron than Delta after 2 and 3 doses has been documented, protection that may also wane faster over time [14,17-19]. However, a recent preliminary report found no difference in severity between Omicron and Delta [16]. While some studies have stratified results by vaccination status [13-15] and age [13], none have comprehensively evaluated the simultaneous impact of these and other important factors (e.g., chronic medical conditions, frailty) on more detailed measures of relative clinical severity in hospitalized patients.

In this study, we assessed the relative impact of SARS-CoV-2 variant (i.e., Omicron versus Delta) on three separate measures of severity of COVID-19-related hospitalization after adjusting for important potential confounders, such as age, frailty, and vaccination status. Our results should facilitate public health and hospital service planning.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

METHODS

Study design and study population

We are conducting a prospective cohort study of adults with acute respiratory illness admitted to North Bristol and University Hospitals Bristol and Weston NHS Trusts and now report those presenting between 1st June 2021 and 28th March 2022 inclusive. All adults aged ≥18 years admitted to these hospitals were screened for signs and symptoms of respiratory disease as reported previously [20]. Of these, patients who tested positive for COVID-19 as detailed below were included.

UK Vaccination Programme

The UK vaccine programme prioritised first dose administration, extending the interval between first and second doses of COVID-19 vaccines up to 12 weeks [21]. Initially BNT162b2 (Comirnaty®) was deployed in the UK, followed rapidly by the addition of ChAdOx1 (Vaxzevria®) and, subsequently, mRNA-1273 (Spikevax®). After January 2022, coverage with 2 doses of vaccine was over 80% in adults aged ≥20 years of age with higher rates among those ≥50 years of age [22]. A booster campaign delivering a third vaccine dose commenced in September 2021 and was accelerated in December 2021 to meet the emerging threat of Omicron [23], resulting in 60% of adults receiving a booster by 1st January 2022. Both the primary vaccination campaign and the booster campaign were rolled out in an age-stratified fashion, with elderly and high-risk groups targeted first [2].

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Data Collection

Clinical data were collected from electronic and paper patient records and recorded on an electronic case report form using REDCap software [24]. Data collection was undertaken by individuals not involved in data analysis and methods were identical for patients with Omicron and Delta variant infections. Vaccination records for each study participant were obtained by team members unaware of subjects' SARS-CoV-2 test results from linked hospital and GP records, including details of vaccination brand and date of administration. The QCovid2 hazard score, which includes components for age, deprivation, body mass index (BMI), and pre-existing disease, was calculated for each admission [25], in addition to the Charlson Comorbidity Index (CCI) [26,27].

Case definitions and exclusions

SARS-CoV-2 infection was defined as respiratory disease and a positive test result for SARS-CoV-2 on/during admission or within 7 days prior to admission, using the established UK Health Security Agency (UKHSA) diagnostic assay deployed at the time. Infection with a particular SARS-CoV-2 variant was likewise determined using the standard UKHSA variant identification methods deployed at the time. Initially, Delta was identified by S-gene positive PCR (SGTP), which was replaced on 11th May 2021 by the P681R target following validation. Omicron was identified as S-gene negative (SGNP) and then by K417N mutation [28]. Cases without variant identification results admitted between the 1st June 2021 and 7th November 2021 were inferred to be Delta, and those after 7th Feb 2022 were inferred to be Omicron. These two dates represent the first date of a proven Omicron admission and the last date of a proven Delta admission in the Bristol area, respectively.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Patients developing symptoms >10 days prior to admission were excluded to avoid including individuals who may have falsely tested negative for SARS-CoV-2 upon admission because they presented to hospital late in their clinical course as were individuals who had been inpatients for >28 days prior to their first positive SARS-CoV-2 PCR test. Patients who were partially vaccinated, i.e. had received only one dose or a second dose <7 days before the time of symptom onset, and those who had previously recovered from COVID-19 and not been vaccinated, were also excluded from the analysis. Individuals were defined as unvaccinated if they had never received any COVID-19 vaccine. Immunisation with only two vaccine doses was defined as receipt of two doses with ≥7 days elapsing between symptom onset and the second dose (and no third dose). Immunisation with three doses was defined as receipt of a third vaccine dose after receiving two doses, with ≥7 days elapsing between the third dose and symptom onset. Only patients being admitted with COVID-19 for the first time were included, as repeat admissions may be expected to follow different clinical courses.

Outcome and covariates

The primary comparison is between cases infected with SARS-CoV-2 Delta variant and SARS-CoV-2 Omicron variant. To investigate disease severity and consider the hypothesis that Omicron is associated with less severe outcomes in patients hospitalised with COVID-19, we considered three separate binary outcomes measured on the seventh day following admission: (1) maximum oxygen requirement FiO_2 >28%, (2) a WHO outcome score greater than 5 (i.e. ventilation or intubation required or death) within the first seven days of hospitalisation [29], and (3) length of stay longer than three days. The WHO outcome score, or clinical progression scale is based on the level of invasive ventilation required and, in admitted patients, scores range from

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

4 to 10 (4 = room air, 5 = oxygen supplementation required, 6 = non-invasive positive pressure ventilation [NIPPV] usage, and 7-9 needing endotracheal intubation). A score of 10 represents death. Outcome measures were chosen to reflect different operational concerns for hospitals, in particular the adequacy of oxygen supply, availability of high dependency care, and a measure of overall hospital bed utilisation. We measured the scores at day seven to include relevant data from the hospital admission and to prevent complications with right censoring. Thresholds for the outcomes used here were determined empirically following an initial investigation, and a sensitivity analysis conducted on the level of each threshold.

Statistical Analysis

The demographics of patients with Delta infection and those with Omicron were compared using Fisher exact tests for categorical variables, two sided Kolmogorov–Smirnov tests for continuous variables and two-sided Wilcoxon-Mann-Whitney tests for score variables. Where data were missing, this comparison was performed with both the missing data removed and with missing data included as a separate category (Table 1).

The complex interaction between the dynamics of variant distribution in the UK and the progressing age-stratified booster campaign rollout was hypothesised to influence both the risk profile of patients hospitalised and severity of outcome once hospitalised. The outcomes are relatively frequent in both groups which can make interpretation of odds ratios resulting from logistic regression complex [30]. Thus, we used Poisson regression with a robust error variance [30] to estimate the relative risk of each of the three outcomes described above.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

The primary comparison was the impact of the variant (i.e., Delta versus Omicron) on hospital outcomes. Other covariates were identified that might also influence the outcomes, which included: vaccination status; age (categorical); markers of frailty (Charlson Comorbidity Index [CCI] [26], QCovid2 hazard, [25], Rockwood score [31]); gender; ethnicity; immunosuppressive therapy; residence in a care home; index of multiple deprivation; duration of symptoms prior to admission; hospital site and study week number. The distribution of these variables with respect to variant are shown in Supplementary Table 3. These covariates were screened for systematic biases due to missing data, resulting in removal of index of multiple deprivation (Supplementary Tables 4 and 5). Remaining missing data were imputed using the fully conditional specification approach implemented using the `mice` package in R [32]. Multiple imputations were performed and the full analysis repeated for each imputation. For each of the factors and outcomes, the univariate relative risk was estimated, followed by a multivariable model of a linear combination of genomic variant, vaccination, age and CCI [26]. These were then fully adjusted using the remaining covariates, gender, ethnicity, immunosuppressive therapy, residence in a care home, duration of symptoms prior to admission, hospital site, and study week number. The resulting coefficients for each imputation were combined using a mixture distribution, assuming normally distributed beta coefficients. Sensitivity analyses were conducted using different combinations of age and frailty markers, including CCI as a continuous variable, Rockwood score [31] and the QCovid2 hazard rate (which includes age) [25]. Further sensitivity analyses were conducted looking at different threshold values of each of the three binary outcomes.

Statistical analyses were performed in R, version 4.0.2. Robust Poisson regression was performed using maximum likelihood estimation of a generalised linear model, with a positive

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

outcome encoded as a count of 1 and negative outcome as 0. We employed a logarithmic link function, and heteroscedasticity consistent covariance matrix estimators. [30,33] Statistical significance was defined using a 2-sided significance level of $\alpha = 0{\cdot}05$. We also conducted a sensitivity analysis on the statistical model using quasi-Poisson and log-binomial regression giving relative risks and logistic regression giving odds ratios for completeness.

Ethics and permissions

The study was approved by the Health Research Authority Research Ethics Committee (East of England, Essex), REC 20/EE/0157, including data collection under Section 251 of the 2006 NHS Act authorised by the Confidentiality Advisory Group.

Role of the funding source

The funders of the study did not play any part in data collection; they collaborated in the design of the study, data analysis and manuscript preparation.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

RESULTS

During the study period reported here, 3297 admissions with SARS-CoV-2 were identified, resulting in 1938 SARS-CoV-2 positive qualifying admissions: 1190 with Delta variant and 748 with Omicron variant. 59 Delta and 22 Omicron cases were excluded from analysis as described in Figure 1.

Patients hospitalised with the Omicron variant were statistically older than those with Delta infection (median [IQR]: 70·6y [44·8y – 83·5y] versus 57·7y [42·6y – 74·1y] respectively, $P<0.001$) and had a higher CCI (4 [1 – 5] versus 2 [0 – 4] respectively, $P<0·001$). These individuals were also more likely to have received a third vaccination dose (60·2 versus 5·0% respectively, $P<0·001$) (Table 1). Additional analysis investigated the nature of the additional comorbidities (Supplementary Table 1) and detail of vaccination (Supplementary Table 2), showing that patients admitted with Omicron infection were more likely to have pre-existing heart disease, hypertension, atrial fibrillation, dementia, mild chronic kidney disease (CKD), and peripheral vascular disease than patients admitted with Delta infection (all $P<0.001$).

The proportion of hospitalisations with the Omicron variant increased over time and became the dominant variant in the last week of December 2021 (Figure 2A). As the vaccination campaign progressed over the course of the study period, we saw increasing proportions of admissions of individuals who had received two vaccine doses or a booster (Figure 2B). Admissions occurring early in the study period tended to be younger individuals, and the age profile of admissions shifted towards older groups with time, with evidence of a change point in late December 2021, coincident with the increase in Omicron cases (Figure 2C). Overall, the patterns suggest that

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

patients admitted between December and February were generally older and frailer, but more commonly vaccinated.

In addition to being older, frailer, and more frequently vaccinated, patients admitted with Omicron infections experienced less severe outcomes compared to patients infected with Delta. Omicron admissions required ventilation less frequently (Figure 3A), and when they did, a lower oxygen supplement was needed (Figure 3B). The WHO outcome score was also lower within the first seven days of admission (Figure 3C). There was no discernible difference in these outcomes between Delta and Omicron in patients ≥85 years of age (Figure 3D and 3E). Length of hospital stay was shorter for Omicron compared to Delta among patients <70 years of age but was similar for those ≥70 years (Figure 3F).

Direct associations (Figure 3) account for neither the changes in patient frailty nor vaccination status observed over the course of the study. Figure 4 presents results of adjusted regression models that account for these time-varying factors observed over the duration of the study (methodological details in Supplementary Tables 3-11, numerical results in Supplementary Tables 12 & 13). Relative to Delta, patients infected with Omicron were less likely to require oxygen supplementation of FiO_2 >28% [RR = 0·42 (95% CI: 0·34-0·52)], to have a WHO outcome score >5 (which implies that a patient required positive pressure ventilatory support or died in the hospital) [RR = 0·33 (95% CI: 0·21-0·50)], and to have a hospital stay lasting over three days [RR = 0·84 (95% CI: 0·76-0·92)]. In stratified analyses by vaccination status, infection with Omicron relative to Delta was associated with lower severity across all three measures in both vaccinated and unvaccinated patients.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Compared to unvaccinated patients, those who were vaccinated with two doses were less likely to require high flow oxygen >28% FiO_2 [RR = 0·78 (95% CI: 0·68-0·89)], positive pressure ventilatory support or increased critical care [RR = 0·56 (95% CI: 0·43-0·73)], and to have a hospital admission >3 days [RR = 0.90 (95% CI: 0·84-0·98)]. Results for vaccination with three doses were similar but had wider confidence intervals than for two doses. In analyses stratified by infecting variant, vaccination was associated with lower severity of disease using all three measures for both Omicron and Delta infections. In analyses assessing potential effect modification by adding an interaction term between variant and vaccination status to adjusted models, the interaction term was not significant for any severity outcome (Supplementary Table 14).

In sensitivity analyses using threshold levels of increased severity to dichotomize outcomes, the relative lower severity of Omicron declined further when using higher thresholds for oxygen requirement [FiO_2 >35%: RR = 0·27 (95% CI: 0·19-0·39); FiO_2 >50%: RR = 0·23 (95% CI: 0·15-0·37); Supplementary Table 15]. Sensitivity analysis using a WHO outcome score threshold >6 (and hence necessitating intubation) had insufficient statistical power (Supplementary Table 16). When longer thresholds for LOS were used, the lower relative severity of Omicron attenuated as the threshold increased [LOS >5 days: RR = 0·81 (95% CI: 0·71-0·92); LOS >7 days: RR = 0·85 (95% CI: 0·73-0·99); Supplementary Table 17], suggesting that certain patient characteristics may be associated with shorter hospital admissions. For vaccination, the protective effect of vaccines increased as the severity level threshold increased for each outcome

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

measure. Associations were similar in sensitivity analyses that replaced age group and the Charlson comorbidity index with the QCovid2 score.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

DISCUSSION

We found evidence that infection with Omicron was associated with less severe illness than that caused by Delta and that vaccination was independently associated with lower in-hospital disease severity using three separate measures of severity. Specifically, compared to Delta, Omicron-related hospitalizations were 58%, 67%, and 16% less likely to require high flow oxygen >28% FiO_2, positive pressure ventilatory support or more critical care, and to have a hospital stay lasting more than three days, respectively. These findings persisted even after controlling for multiple potential confounders including age, chronic medical conditions, frailty, and increasing vaccination coverage over time. Our findings are in keeping with previously published assessment of the relative severity of Omicron variant infection compared to other variants, which examined markers of severity such as hospitalization, ICU admission, mechanical ventilation, severe disease and death [34,35]. Further, by determining the reduced requirement of increased oxygen requirement and total positive pressure requirement, including non-invasive ventilation, this analysis should contribute to future hospital care and service planning assessments.

From a public health perspective, the impact of the lower severity of Omicron-related hospitalization must be balanced with increased transmissibility and overall higher numbers of infections due to this variant. Even with the reduced risk of severe disease posed by Omicron, this may result in substantial pressure on the hospital system due to increased bed occupancy, as the less severe variant is offset by the increasingly elderly and frail patients requiring hospital care. Further, considerable morbidity resulted from Omicron infection, with 18% of Omicron admissions requiring oxygen supplementation of FiO_2 >28%, 6% requiring positive pressure

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

ventilation, 62% resulting in hospital stays lasting four days or longer, and 4% resulting in in-hospital mortality. Despite the reduction in individual-level risk of needing high flow oxygen or high dependency care with Omicron compared to earlier variants, healthcare systems could still be overwhelmed by the sheer number of cases and the resulting high (absolute) number of hospitalizations. Omicron's increased transmissibility also increases the risk of infection for clinical and other hospital staff, which can take a significant toll on the number of staff available to provide care. The hospital burden of COVID-19 is influenced by: (a) the community prevalence of SARS-CoV-2 infection, (b) the relative frequency and intrinsic severity of circulating SARS-CoV-2 variants, (c) the inherent risk of severe disease among those infected, (d) the modification of this risk resulting from vaccination, and (e) any limitations on the end-to-end function of health and social care. These factors all vary with time in our analysis. Determining their relative importance helps us to identify elements of the health service that may be most affected by the high incidence of community COVID-19 disease caused by the Omicron variant.

Discerning the effect of a variant on hospital length of admission in the context of individuals who have already developed severe enough disease to merit hospital level care is difficult. Multiple factors affect duration of admission which confound the effect of any individual pathogen or pathogen strain, including patient frailty and their need for continued care following discharge. Other events unrelated to the patient's primary pathology, such as inpatient falls or secondary hospital-acquired infection, may also impact discharge. In contrast, the reductions in oxygen requirements and lower WHO outcome scores we observe for Omicron infections are reassuring. This suggests that exhaustion of oxygen supplies or high dependency care beds are

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

less likely to be seen in large waves of community Omicron infection than was the case with Delta and other previous variants. Vaccination is seen to reduce these risks further and our results suggest it is an important modifier of these aspects of impact on health services.

Our results are in line with prior studies reporting that infection with Omicron was less likely to result in severe disease compared to infection with Delta, in both vaccinated and unvaccinated individuals [13-15]. Lauring *et al*. also reported lower in-hospital severity for Omicron than for Delta among unvaccinated patients, and that severity was significantly lower for vaccinated patients, for both Omicron and Delta infections. Although additional studies have reported lower intrinsic severity for Omicron relative to Delta, measured as the risk of hospitalization [13,15] or death [13] following infection after taking into account vaccination status, the scientific evidence continues to evolve. A recent preliminary report found no difference in severity between the two variants with regards to risk of hospitalization or mortality [14].

Our study has several strengths. All patients were admitted to hospital with acute respiratory illness caused by SARS-CoV-2, so these results are unlikely to be subject to bias caused by admission for other causes (i.e., incidental COVID-19 disease). In the UK, all national programme vaccines are provided at no cost at the point of delivery; hence our cohort is not biased by issues surrounding the cost of vaccination that are seen in fee-based systems [36]. While week of symptom onset was identified as a significant univariate predictor for adverse outcome, we observe it becomes non-significant on a multivariable analysis which includes time varying factors, such as vaccination, or variant status (Supplementary Tables 6, 8, 10). This

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

reassures us that there are no other time varying factors for which we have not accounted. With a comparatively rich data set of prospectively collected information, we can determine timing of disease onset accurately and capture information on a range of factors more precisely, such as vaccination status and patient comorbidities, than could be done using a retrospective design. However, we are limited in this study to observation of patient outcomes in patients only after hospital admission. Thus, we cannot draw conclusions about the severity of Omicron infections occurring entirely in the community. We observed a change in the demographics of patients being admitted towards more elderly and frail populations, which could be explained if community Omicron disease were especially milder in young and healthy individuals. The effects we observed for Omicron and vaccination on clinical outcomes in hospitalised patients occurred over and above any community-level effects. We did not have sufficient data to determine the effectiveness of any individual vaccine against the outcomes studied and our results cannot be interpreted as a vaccine effectiveness estimate. Furthermore, we did not have sufficient statistical power to determine with confidence whether booster doses of COVID-19 vaccine offered additional protection against adverse outcomes. We are unable to control for pressures in the social care system following discharge, and large waves of community Omicron infection may put pressure on community elderly care facilities resulting in a backward pressure on hospital discharges. This could partially explain our observation that length of stay longer than three days is less associated with variant status and vaccination than other outcomes. Whilst the population of the Bristol area is representative of the UK population, it is principally Caucasian, and our findings must be interpreted in this context.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

In this prospective study, patients hospitalised with Omicron infections had lower clinical severity than those with Delta infections, as assessed by maximal oxygen requirements, a validated WHO outcome score, and hospital length of stay. Omicron infection, however, still resulted in substantial patient and public health burden following admission. Elderly and frail patients remain particularly susceptible to severe SARS-CoV-2 infection, underscoring the importance of maintaining high levels of vaccine coverage in this population. Understanding differences in the risk of clinical disease caused by SARS-CoV-2 variants following infection and following hospitalisation, and the role of vaccination and other factors in modifying risk, is critical for planning of public health measures.

TABLES

Table 1: Baseline Characteristics of Adults Hospitalised with Delta and Omicron SARS-CoV-2 Infection.

Confidence intervals shown are the 95% binomial confidence interval for each group, compared to other groups. *P*-values are shown for the comparison excluding missing values, and in parentheses for the comparison including missing values as a separate category. BMI – body mass index, CCI – Charlson Comorbidity Index, HR – Hazard Ratio, IQR – interquartile range, SD – standard deviation

Characteristic	**Group**	**Delta**		**Omicron**		***P*-value**
		N	**Value**	**N**	**Value**	
Age	Median [IQR]	1114	57·7 [42·6 – 74·1]	679	70·6 [44·8 – 83·5]	<0·001
Gender	Male	628	56·4% [53·4–59·3]	349	51·4% [47·6–55·1]	0·045 (0·045)
	Female	486	43·6% [40·7–46·6]	330	48·6% [44·9–52·4]	
Race	White British	669	60·1% [57·1–62·9]	463	68·2% [64·6–71·6]	0·025 (0·020)
	White other	72	6·5% [5·2–8·1]	28	4·1% [2·9–5·9]	
	Mixed origin	11	1·0% [0·6–1·8]	5	0·7% [0·3–1·7]	
	Black	39	3·5% [2·6–4·7]	19	2·8% [1·8–4·3]	
	Asian	45	4·0% [3·0–5·4]	21	3·1% [2·0–4·7]	
	Other race	21	1·9% [1·2–2·9]	7	1·0% [0·5–2·1]	
	Unknown	257	23·1% [20·7–25·6]	135	19·9% [17·1–23·0]	
	Missing	0	0·0% [0·0–0·3]	1	0·1% [0·0–0·8]	
BMI	Median [IQR]	703	29·1 [24·7 – 33·3]	192	25 [21·4 – 29·9]	<0·001
CCI category	None (0)	349	31·3% [28·7–34·1]	167	24·6% [21·5–28·0]	<0·001 (<0·001)
	Mild (1-2)	253	22·7% [20·3–25·3]	98	14·4% [12·0–17·3]	
	Moderate (3-4)	247	22·2% [19·8–24·7]	186	27·4% [24·2–30·9]	
	Severe (5+)	265	23·8% [21·4–26·4]	228	33·6% [30·1–37·2]	
Vaccination	Unvaccinated	551	49·5% [46·5–52·4]	164	24·2% [21·1–27·5]	<0·001 (<0·001)
	2 doses	507	45·5% [42·6–48·4]	106	15·6% [13·1–18·5]	
	3 doses	56	5·0% [3·9–6·5]	409	60·2% [56·5–63·8]	
On immunosuppression	No	1033	92·7% [91·1–94·1]	631	92·9% [90·8–94·6]	0·567 (0·031)
	Yes	81	7·3% [5·9%–8·9%]	44	6·5% [4·9%–8·6%]	
	Missing	0	0·0% [0·0%–0·3%]	4	0·6% [0·2%–1·5%]	

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

FIGURE LEGENDS

Figure 1: CONSORT diagram of adults hospitalised with SARS-CoV-2 infection

Inclusion and exclusion criteria in the cohort stratified by the primary comparison or SARS-CoV-2 variant. Any patient may be excluded for multiple reasons at each stage, hence the counts of reasons for exclusion may not add up to the number of patients excluded.

FiO_2, fraction of inspired oxygen; LOS, length of stay; VOC, variant of concern; WHO, World Health Organisation

Figure 2: Hospitalisations with SARS-CoV-2 infection throughout the study

(A) Daily rates of hospitalisations with Delta and Omicron SARS-CoV-2 infection, (B) 14-day rolling proportions of hospitalisations by vaccination status (excluding people partially vaccinated on admission) and (C) by age groups (in years) throughout the study. Vertical lines represent the earliest time an Omicron case was admitted and the latest time a Delta case was admitted. Outside this date range all cases are assumed to be Delta or Omicron when sequencing results are not available.

Figure 3: The detailed breakdown of the three selected indicators of severity of hospital admission stratified by SARS-CoV-2 variant, and the comparison of three binary indicators of hospital burden and their relationship to SARS-CoV-2 variant and patient age, for patients admitted to hospital.

The distribution of patients (A) requiring different peak levels of oxygen supplementation, (B) with different ventilation requirements as defined by the WHO outcome or clinical progression

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

score, and (C) with different lengths of stay. The proportion of patients who (D) require high flow oxygen >28% FiO_2, (E) have a WHO outcome score>5 (requiring NIPPV), and (F) have a hospital length of stay greater than three days, as assessed on the seventh day following admission. Error bars show 95% binomial confidence intervals for each outcome, compared to other outcomes.

FiO_2, Fraction of inspired oxygen; LOS, length of stay; NIPPV, non-invasive positive pressure ventilation

Figure 4: Robust Poisson regression model relative risks for the three indicators of hospital burden.

Relative risks describing the effect of different predictors on whether patients require oxygen supplementation with FiO_2 >28% (first column), have a WHO outcome score greater than 5 (second column) or who remain in hospital for more than 3 days (third column) measured on the seventh day after admission. Numerical details of these regression models, including other explanatory variables that are not our primary interest, are given in Supplementary Table 15. A comparison of relative risks computed by different methods and odds ratios by logistic regression is shown in Supplementary Table 18.

FiO_2 – fraction inspired oxygen, LOS – length of stay, CCI – Charlson Comorbidity Index

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

DATA SHARING

The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality rules.

CONTRIBUTORS

CH, RC, RM, LD, JO, JN, JM and AF generated the research questions and analysis plan. CH, AM, JK, MC and The Avon CAP team were involved in data collection. CH, RC, RM, LD, and AF undertook data analysis. All authors were involved in the final manuscript preparation and its revisions before publication. AF provided oversight of the research.

FUNDING

This study is a University of Bristol sponsored study which is funded under an investigator-led collaborative agreement by Pfizer Inc.

DECLARATIONS OF INTEREST

CH is Principal Investigator of the Avon CAP study which is an investigator-led University of Bristol study funded by Pfizer and has previously received support from the NIHR in an Academic Clinical Fellowship. JO is a Co-Investigator on the Avon CAP Study. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation. LD, RC are members of SPI-M-O subgroups of SAGE and

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

are also partly funded through AvonCAP. LD is a Co-Investigator of the AvonCAP study and has also received funding from Pfizer, UKRI and UKHSA for unrelated projects. EB, JS, JN, GE, LJ, BG, and JM are employees of Pfizer, Inc and may hold stock or stock options. The other authors have no relevant conflicts of interest to declare.

ACKNOWLEDGEMENTS

The authors would like to thank the UK Health Security Agency (UKHSA) Vaccine Effectiveness Working group and the University of Bristol UNCOVER group for guidance in data analysis and study design. We thank colleagues at the University of Bristol for their support with this study, including Rachel Davies, Paul Savage, Emma Foose, Susan Christie, Mark Mummé, and Adam Taylor. We would also like to acknowledge the research teams at North Bristol and University Hospitals of Bristol and Weston NHS Trusts for making this study possible, including Helen Lewis-White, Rebecca Smith, Rajeka Lazarus, Mark Lyttle, Kelly Turner, Jane Blazeby, Diana Benton, and David Wynick. We would also like to acknowledge all participants of the many studies undertaken to find effective vaccines against SARS-CoV-2.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

REFERENCES

1. Challen R, Dyson L, Overton CE, et al. Early epidemiological signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in England. *medRxiv* 2021: 2021.06.05.21258365.
2. Government U. Coronavirus (COVID-19) in the UK. 2022. https://coronavirus.data.gov.uk/details/vaccinations?areaType=overview&areaName=United%20Kingdom (accessed 14 February 2022).
3. UKHSA. SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 36. 2022.
4. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. *Nature* 2021; **593**(7857): 130-5.
5. Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. *New England Journal of Medicine* 2021; **384**(15): 1466-8.
6. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. *New England Journal of Medicine* 2021; **386**(5): 492-4.
7. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *New England Journal of Medicine* 2021; **386**(6): 599-601.
8. Ferguson N, Ghani A, Hinsley W, Volz E. Report 50: Hospitalisation risk for Omicron cases in England. *Imperial College London* 2022.
9. Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland. *University of Edinburgh* 2021.
10. Jassat W, Abdool Karim SS, Mudara C, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. *The Lancet Global Health*.
11. Kirsebom FCM, Andrews N, Stowe J, et al. COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. *Lancet Infect Dis* 2022.
12. UKHSA UHSA. COVID-19 vaccine surveillance report: week 19. 2022. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1075115/COVID-19_vaccine_surveillance_report_12_May_2022_week_19.pdf (accessed 8th June 2022 2022).
13. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *The Lancet*.
14. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. *BMJ* 2022; **376**: e069761.
15. Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. *Lancet Infect Dis* 2021; **21**(11): 1507-17.
16. Strasser Z, Hadavand A, Murphy S, Estiri H. SARS-CoV-2 Omicron Variant is as Deadly as Previous Waves After Adjusting for Vaccinations, Demographics, and Comorbidities. *Research Square* 2022.
17. UKHSA. COVID-19 vaccine surveillance report: Week 11: UK Government, 2022.
18. Ferdinands J, Rao S, Dixon B, al e. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**: 255-63.
19. Thompson M, Natarajan K, SA I, al e. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**: 139-45.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.29.22277044; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

20. Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. *The Lancet Infectious Diseases* 2021; **21**(11): 1539-48.
21. JCVI. Optimising the COVID-19 vaccination programme for maximum short-term impact. 26th January 2021 2021. https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact (accessed 24th February 2021).
22. UKHSA. COVID-19 vaccine surveillance report - Week 51. 2021.
23. England N. NHS begins COVID-19 booster vaccination campaign. 2021.
24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Informatics* 2009; **42**(2): 377-81.
25. Hippisley-Cox J, Coupland CAC, Mehta N, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. *BMJ* 2021; **374**: n2244.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. *Journal of Chronic Diseases* 1987; **40**(5): 373-83.
27. Physicians RCo. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. *RCP, London* 2017.
28. UKHSA. SARS-CoV-2 variants of concern and variants under investigation in England, Technical Briefing 33, 2021.
29. Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis* 2020; **20**(8): e192-e7.
30. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol* 2004; **159**(7): 702-6.
31. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 2005; **173**(5): 489-95.
32. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software* 2011; **45**(3): 1 - 67.
33. Zeileis A, Köll S, Graham N. Various Versatile Variances: An Object-Oriented Implementation of Clustered Covariances in R. *Journal of Statistical Software* 2020; **95**(1): 1 - 36.
34. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California. *Nature Medicine* 2022.
35. Van Goethem N, Chung PY, Meurisse M, et al. Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021–2022. *Viruses* 2022; **14**(6).
36. Wheelock A, Miraldo M, Thomson A, Vincent C, Sevdalis N. Evaluating the importance of policy amenable factors in explaining influenza vaccination: a cross-sectional multinational study. *BMJ Open* 2017; **7**(7): e014668.


3297 SARS-CoV-2 positive admissions
568: SARS-CoV-2 positive, with no known/inferred VOC
Inclusions:
2460 Known Delta or Omicron Infection
269 Inferred Delta or Omicron Infection
342: <2 symptoms, or not proven respiratory infection
1: first dose BNT162b2 before 08/02/2020
266: symptom onset >10 days before admission
260: repeat admissions
1938 subjects
59 partially vaccinated
19 Hospital-acquired infection
Delta Variant **1190** subjects
Omicron Variant **748** subjects
19 partially vaccinated
47 Hospital-acquired infection
Delta Variant **1114** subjects
Omicron Variant **682** subjects
3 missing day FiO_2, LOS and WHO score outcome
Delta Variant **1114** subjects
Omicron Variant **679** subjects


A
admissions per day
20
15
10
5
0
Delta
Omicron
B
proportion
1.00
0.75
0.50
0.25
0.00
Unvaccinated
2 doses
3 doses
C
proportion
1.00
0.75
0.50
0.25
0.00
18-34
35-49
50-64
65-74
75-84
85+
2021-05-31
2021-06-14
2021-06-28
2021-07-12
2021-07-26
2021-08-09
2021-08-23
2021-09-06
2021-09-20
2021-10-04
2021-10-18
2021-11-01
2021-11-15
2021-11-29
2021-12-13
2021-12-27
2022-01-10
2022-01-24
2022-02-07
2022-02-21
2022-03-07
2022-03-21
2022-04-04
admission date


A
proportion
0.0
0.2
0.4
0.6
room air
24-28%
30-35%
40%
50%
60%
80%
Over 80%
Max FiO2
B
proportion
0.0
0.2
0.4
0.6
score 4
score 5
score 6
score 7-8
score 9
score 10
WHO Outcome score
C
proportion
0.0
0.1
0.2
0.3
0.4
0 day
1 day
2 days
3 days
4 days
5 days
6 days
7 days
still inpatient
Length of Stay
Delta
Omicron
D
% on >28% FiO2
0
20
40
60
18-34
35-49
50-64
65-74
75-84
85+
E
% with WHO Outcome > 5
0
10
20
30
18-34
35-49
50-64
65-74
75-84
85+
F
% with LOS > 3 days
20
40
60
80
18-34
35-49
50-64
65-74
75-84
85+



††† indicates p-value < 0.001, †† p-value < 0.01 and † p-value < 0.05. 'ns' have p-value ≥ 0.05